Atara Biotherapeutics Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 23rd. The stock was sold at an average price of $18.34, for a total value of $220,080.00. Following the sale, the chief executive officer now directly owns 555,044 shares of the company’s stock, valued at $10,179,506.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded up 6.28% during trading on Wednesday, reaching $19.45. The company had a trading volume of 196,158 shares. The firm’s market capitalization is $561.33 million. The firm’s 50 day moving average price is $16.69 and its 200 day moving average price is $19.65. Atara Biotherapeutics Inc. has a 12-month low of $12.45 and a 12-month high of $40.80.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Friday, November 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by $0.10. Equities research analysts forecast that Atara Biotherapeutics Inc. will post ($3.05) EPS for the current year.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

A number of brokerages have commented on ATRA. Canaccord Genuity set a $47.00 price objective on Atara Biotherapeutics and gave the stock a “buy” rating in a report on Sunday, November 6th. Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 26th. Jefferies Group began coverage on Atara Biotherapeutics in a report on Monday, October 24th. They set a “buy” rating and a $23.00 price objective for the company. Goldman Sachs Group Inc. lowered Atara Biotherapeutics from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $23.00 to $16.00 in a report on Thursday, September 15th. Finally, Citigroup Inc. upped their target price on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a report on Friday, August 19th. Three analysts have rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $25.86.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its stake in shares of Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock valued at $108,000 after buying an additional 4,600 shares during the last quarter. Panagora Asset Management Inc. bought a new stake in shares of Atara Biotherapeutics during the third quarter valued at approximately $110,000. BlackRock Group LTD boosted its stake in shares of Atara Biotherapeutics by 3.7% in the third quarter. BlackRock Group LTD now owns 5,532 shares of the company’s stock valued at $119,000 after buying an additional 198 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock valued at $137,000 after buying an additional 5,019 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock valued at $148,000 after buying an additional 6,467 shares during the last quarter. Institutional investors own 74.45% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Atara Biotherapeutics Inc. (ATRA) CEO Sells $220,080.00 in Stock” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/23/atara-biotherapeutics-inc-atra-ceo-sells-220080-00-in-stock.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.